This collection
is approved. FDA should provide OMB and update of its efforts to
develop a national xenotransplantation database within 6
months.
Inventory as of this Action
Requested
Previously Approved
01/31/2004
01/31/2004
53
0
0
343
0
0
0
0
0
The PHS guideline recommends
procedures to diminish the risk of transmission of infectious
agents to the xenotransplantation product recipient and the general
public. The collection of information described in this guideline
will provide general guidance to sponsors in the development of
xenotransplantation clinical protocols, in preparing submissions to
FDA, and in the conduct of xenotransplantation clinical trials.
Also, the collection of information will help ensure that the
sponsor maintains important information in a cross-referenced
system that links the relevant records of the xenotransplantation
product....
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.